National Institutes of Health

SonoMotion Inc. is a medical device company focused on developing non-invasive solutions for kidney stone disease. Founded in 2012 and based in San Mateo, California, the company offers innovative products like Break Wave, which effectively fragments large kidney stones, and Stone Clear, designed to clear the resulting fragments within 15 minutes in an office setting without the need for general anesthesia or X-ray radiation. Additionally, SonoMotion is advancing its technology with a stone repositioning solution currently in clinical trials and a second-generation stone breaking technology in development. The company's mission is to provide caregivers with safe, efficient, and cost-effective treatment options for patients suffering from kidney-related ailments.

Vast Therapeutics, Inc. is a preclinical-stage pharmaceutical company based in Durham, North Carolina, focused on developing inhalable treatments for antibiotic-resistant pathogens affecting patients with cystic fibrosis and other respiratory diseases. Established in 2017 and previously known as Novoclem Therapeutics, the company aims to address chronic infections that are prevalent in the cystic fibrosis population. Vast Therapeutics operates as a subsidiary of KNOW Bio, LLC, and is dedicated to advancing its innovative therapeutic solutions to improve health outcomes for patients facing these challenging conditions.

Arkansas Children's Research Institute is a not-for-profit organization affiliated with Arkansas Children's, Inc., and is dedicated to advancing pediatric health through research. It operates in conjunction with Arkansas Children's Hospital, the only pediatric medical center in Arkansas and one of the largest in the nation, which spans 29 city blocks and features 370 beds. The hospital employs around 500 physicians and more than 4,400 staff members, focusing on innovative medical research, surgical procedures, and intensive treatments aimed at improving children's health and development. The institute's research efforts contribute to the hospital's reputation for medical breakthroughs and have garnered recognition, including being ranked on the FORTUNE 100 Best Companies to Work For list for three consecutive years.

Feinstein Institute For Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State. Home to 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine.

University of Arkansas for Medical Sciences is an academic health center focusing on medical education, research, and clinical programs. It offers various medical services, including specialized care in areas such as women's health, cancer treatment, orthopedics, stroke care, and trauma.

Sparian Biosciences is an early-stage biopharmaceutical company dedicated to the discovery and development of innovative therapies for the central nervous system (CNS). The firm specializes in creating unique and transformative medicines that specifically target brain-related conditions. Sparian is committed to advancing therapeutic solutions that address both acute and chronic pain through cutting-edge science and novel drug discovery methods.

Mount Sinai Health System is an integrated healthcare system based in New York, providing exceptional medical care to local and global communities. Established in 2013 through the merger of Mount Sinai Medical Center and Continuum Health Partners, it encompasses the Icahn School of Medicine and operates seven hospital campuses throughout the New York metropolitan area. The system is recognized for its excellence in research, patient care, and education across various specialties. It features a vast network of over 7,000 primary and specialty care physicians, as well as more than 45 ambulatory practices and 12 minority-owned free-standing ambulatory surgery centers. Mount Sinai is committed to improving healthcare quality and accessibility, focusing on compassionate patient experiences and the development of strong relationships between staff and patients. Additionally, its venture capital arm, Mount Sinai Ventures, invests in healthcare startups, further enhancing its capacity to innovate and respond to the diverse health needs of the populations it serves.

Brixton Biosciences is a clinical-stage life sciences company focused on developing innovative therapies for pain management. The company addresses significant unmet needs in both chronic and acute pain treatment, moving beyond traditional systemic approaches. Its flagship product, Neural Ice™, is a drug-free injectable therapy designed to provide safe and effective pain relief through reversible inhibition of nerve activity. This novel solution offers patients a long-lasting relief period, with effectiveness extending from thirty to sixty days following a single injection. By prioritizing non-addictive and locally targeted therapies, Brixton Biosciences aims to transform pain management practices and improve the quality of life for patients suffering from various forms of pain.

Arkansas Children's Research Institute is a not-for-profit organization affiliated with Arkansas Children's, Inc., and is dedicated to advancing pediatric health through research. It operates in conjunction with Arkansas Children's Hospital, the only pediatric medical center in Arkansas and one of the largest in the nation, which spans 29 city blocks and features 370 beds. The hospital employs around 500 physicians and more than 4,400 staff members, focusing on innovative medical research, surgical procedures, and intensive treatments aimed at improving children's health and development. The institute's research efforts contribute to the hospital's reputation for medical breakthroughs and have garnered recognition, including being ranked on the FORTUNE 100 Best Companies to Work For list for three consecutive years.

Allyx Therapeutics, Inc. is a clinical-stage biotechnology company founded in 2018 and based in Durham, Connecticut. The company specializes in developing disease-modifying treatments for Alzheimer's Disease, with a focus on reversing neurodegeneration. Its lead product is an orally bioavailable small molecule that functions as a silent allosteric modulator of mGluR5. This innovative approach aims to provide clinicians with a therapeutic option capable of preserving cognition in patients while addressing the underlying disease mechanisms.

The Oklahoma Medical Research Foundation (OMRF) is a non-profit biomedical research institute dedicated to understanding and treating various devastating illnesses, including Alzheimer's, heart disease, lupus, multiple sclerosis, and cancer. It operates a research facility, providing services and access to resources that facilitate drug discoveries and improve patient care.

Resvita Bio is a biotechnology company focused on developing and manufacturing engineered probiotics specifically designed to treat various skin-related diseases, including cancer. The company utilizes synthetic biology and metabolic engineering to create a versatile skin microbial platform. This platform aims to deliver therapies that reduce inflammation, repair damaged tissue, and eliminate harmful bacteria, offering faster and more effective treatment options for chronic skin conditions.

Cenna Biosciences is a biosciences company focused on the discovery and development of innovative drugs aimed at preventing and treating Alzheimer's disease. The company employs a proprietary mechanism to address the underlying cause of the disease, specifically targeting the inappropriate deposition of toxic ß-amyloid species in the brains of affected patients. Cenna Biosciences has identified a novel target and is actively developing several lead peptide compounds as disease-modifying candidates for Alzheimer's treatment.

Tiziana Life Sciences is a clinical-stage biotechnology company based in London, UK, focused on discovering and developing novel therapeutic molecules for oncology and immunology. The company's product pipeline includes Foralumab, a human anti-CD3 monoclonal antibody aimed at treating autoimmune and inflammatory diseases such as graft-versus-host disease and multiple sclerosis. Another key asset is Milciclib, an orally bioavailable small molecule that inhibits cyclin-dependent kinases and is currently undergoing phase II clinical trials for epithelial thymic carcinoma. Additionally, Tiziana is developing Anti IL-6r, a monoclonal antibody targeting interleukin-6 for severe COVID-19 cases, and StemPrintER, a multi-gene signature assay for estrogen-receptor positive breast cancer patients. Founded in 2013, Tiziana Life Sciences is dedicated to advancing innovative therapies for serious diseases, including neurodegenerative disorders and lung diseases.

TransCode Therapeutics, founded in 2016 and based in Boston, Massachusetts, is a biopharmaceutical company dedicated to discovering, developing, and commercializing microRNA (miRNAs) therapeutics for treating metastatic cancer. The company's core focus lies in its proprietary TTX nanoparticle platform, which enables the intelligent design and effective delivery of RNA therapeutics targeting specific miRNAs. TransCode's lead candidate, TTX-MC138, targets microRNA-10b, a validated biomarker of metastasis across multiple tumor types. By inhibiting this miRNA, TransCode aims to eradicate metastatic tumor cells and combat cancer progression.

Subtle Medical, Inc. is a healthcare technology company based in Menlo Park, California, specializing in AI-powered medical imaging solutions. Founded in 2017, the company develops innovative software products such as SubtleMR and SubtlePET, which are designed to enhance image quality in magnetic resonance imaging (MRI) and positron emission tomography (PET) scans. These products utilize proprietary deep learning algorithms to reduce image noise and improve sharpness, thereby increasing efficiency and safety in clinical workflows. Subtle Medical's technology is FDA cleared and CE marked, and it operates on a vendor-agnostic AI infrastructure that integrates seamlessly with existing imaging systems. The company's mission is to enhance the quality, value, and accessibility of medical imaging by lowering costs, reducing imaging time, and minimizing radiation and contrast doses for patients.

Precision Epigenomics, established in 2020 and based in Tucson, Arizona, specializes in molecular diagnostics for cancer. The company focuses on developing innovative molecular diagnostic assays, leveraging DNA methylation analysis, an epigenetic modification, to enhance cancer diagnosis and treatment. Their offerings aim to address unmet clinical needs, aiding clinicians in improved patient management.

Ensysce Biosciences is a clinical-stage biotechnology company focused on developing safer prescription drugs, particularly in the realm of opioid analgesics. Utilizing its proprietary technology platforms, specifically the Trypsin Activated Abuse Protection (TAAP) and Multi-Pill Abuse Resistance (MPAR), Ensysce aims to create tamper-proof opioids designed to mitigate the risks of addiction and accidental overdose. These innovative drug formulations are intended to provide effective pain relief while reducing the human and economic toll associated with opioid misuse. The company is backed by a comprehensive intellectual property portfolio covering diverse prescription drug compositions, positioning it to make a significant impact on the opioid crisis.

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company based in Houston, Texas, that focuses on developing and commercializing T cell-based immunotherapies and peptide-based vaccines for hematological malignancies and solid tumors. The company’s MultiTAA technology enhances the effectiveness of non-engineered tumor-specific T cells, enabling them to target multiple tumor-associated antigens simultaneously. This approach aims to prevent immune escape and foster durable immunity. Marker Therapeutics offers autologous T cell therapies for conditions such as lymphoma and multiple myeloma, while also developing allogeneic T cell therapies for acute myeloid leukemia and acute lymphoblastic leukemia. Additionally, the company is advancing peptide-based vaccines, including TPIV100/110 and TPIV200, which are currently in Phase II clinical trials for treating breast and ovarian cancers, respectively.

University of Arkansas for Medical Sciences is an academic health center focusing on medical education, research, and clinical programs. It offers various medical services, including specialized care in areas such as women's health, cancer treatment, orthopedics, stroke care, and trauma.

Immunovia is a diagnostics company focused on the early detection of pancreatic cancer and other complex diseases. It develops and commercializes innovative diagnostic tools using its proprietary technology platform, IMMray, which is based on antibody microarray analysis. The company conducts clinical trials and validation studies to ensure the accuracy and reliability of its tests. By collaborating with medical institutions and research centers worldwide, Immunovia aims to bring its diagnostic solutions to market, significantly impacting the treatment and management of pancreatic cancer and potentially improving survival rates. Its approach to utilizing blood-based biomarkers may also enable early detection strategies for other cancers and autoimmune diseases.

Anebulo Pharmaceuticals is a clinical-stage biotechnology company focused on developing innovative treatments for individuals experiencing cannabinoid overdose and substance addiction. Its primary product candidate, ANEB-001, is designed to counteract the adverse effects of cannabinoid overdose within one hour of administration. Clinical trials indicate that ANEB-001 is quickly absorbed and well-tolerated, with additional benefits such as weight loss, which aligns with its action as a central cannabinoid receptor type 1 antagonist. The company aims to address a significant medical need, as symptoms of cannabinoid overdose can vary widely, including severe sedation, anxiety, panic, and psychotic episodes with hallucinations.

Arkansas Children's Research Institute is a not-for-profit organization affiliated with Arkansas Children's, Inc., and is dedicated to advancing pediatric health through research. It operates in conjunction with Arkansas Children's Hospital, the only pediatric medical center in Arkansas and one of the largest in the nation, which spans 29 city blocks and features 370 beds. The hospital employs around 500 physicians and more than 4,400 staff members, focusing on innovative medical research, surgical procedures, and intensive treatments aimed at improving children's health and development. The institute's research efforts contribute to the hospital's reputation for medical breakthroughs and have garnered recognition, including being ranked on the FORTUNE 100 Best Companies to Work For list for three consecutive years.

Weill Cornell Medicine operates as a prestigious medical and graduate school in New York City, dedicated to excellence in education, patient care, and scientific discovery. The institution provides a wide array of services, including medical consultancy, healthcare programs, and educational opportunities for future physicians and medical professionals. It is also involved in the management of specialized treatment centers, such as the Weill Cornell Vein Treatment Center, which addresses various venous conditions and related health issues. In addition to its clinical services, Weill Cornell Medicine emphasizes the integration of advanced technology in its operations, supported by a robust Information Technologies & Services Department. This department enhances the institution's mission by providing comprehensive IT infrastructure and support, including the development of innovative applications for clinical and research projects. Through its multidisciplinary approach, Weill Cornell Medicine serves as a vital resource for healthcare providers, medical students, and researchers, facilitating access to medical education and advisory services across various health-related fields.

Metabolon, Inc. is a health technology company specializing in metabolomics, focusing on the development of diagnostic tests and analytical methods for early disease detection and precision medicine. The company offers a range of clinical diagnostics, including QUANTOSE IR for measuring insulin resistance, QUANTOSE IGT for assessing glucose tolerance, and Meta IMD for identifying metabolites linked to inherited metabolic disorders. In addition to its diagnostic capabilities, Metabolon provides customizable research services and multiomics solutions to support academic and commercial investigations across various life science sectors. Its technologies are applicable in areas such as cardiovascular health, diabetes, oncology, and respiratory disorders. Founded in 2000 and headquartered in Morrisville, North Carolina, with additional offices in Europe and sales locations in the UK, Spain, and China, Metabolon collaborates with numerous strategic partners in the pharmaceutical and biotechnology industries to enhance research and development outcomes.

Ensysce Biosciences is a clinical-stage biotechnology company focused on developing safer prescription drugs, particularly in the realm of opioid analgesics. Utilizing its proprietary technology platforms, specifically the Trypsin Activated Abuse Protection (TAAP) and Multi-Pill Abuse Resistance (MPAR), Ensysce aims to create tamper-proof opioids designed to mitigate the risks of addiction and accidental overdose. These innovative drug formulations are intended to provide effective pain relief while reducing the human and economic toll associated with opioid misuse. The company is backed by a comprehensive intellectual property portfolio covering diverse prescription drug compositions, positioning it to make a significant impact on the opioid crisis.

Arkansas Children's Research Institute is a not-for-profit organization affiliated with Arkansas Children's, Inc., and is dedicated to advancing pediatric health through research. It operates in conjunction with Arkansas Children's Hospital, the only pediatric medical center in Arkansas and one of the largest in the nation, which spans 29 city blocks and features 370 beds. The hospital employs around 500 physicians and more than 4,400 staff members, focusing on innovative medical research, surgical procedures, and intensive treatments aimed at improving children's health and development. The institute's research efforts contribute to the hospital's reputation for medical breakthroughs and have garnered recognition, including being ranked on the FORTUNE 100 Best Companies to Work For list for three consecutive years.

University of Arkansas for Medical Sciences is an academic health center focusing on medical education, research, and clinical programs. It offers various medical services, including specialized care in areas such as women's health, cancer treatment, orthopedics, stroke care, and trauma.

Cincinnati Children’s Hospital Medical Center is a leading institution dedicated to improving child health, attracting patients and families both regionally and internationally. Recognized for its expertise, the hospital serves as a referral center for complex surgical procedures and treatments for rare pediatric diseases. The center is committed to advancing pediatric medicine by discovering innovative and effective treatment methods, solidifying its reputation as one of the foremost facilities for pediatric care globally.

Lamassu Pharma is a biotech startup dedicated to addressing the critical unmet medical need for severe acute pancreatitis. The company is focused on developing a novel small molecule therapy that has shown significant preclinical efficacy in mitigating mortality and morbidity associated with this condition. This therapeutic candidate was developed by leading scientists at Mayo Clinic and aims to improve medical outcomes for patients suffering from severe acute pancreatitis. Currently, Lamassu Pharma is engaged in safety testing of this compound in preparation for definitive clinical trials, with the ultimate goal of saving lives and enhancing the treatment landscape for this serious disease.

University of Arkansas for Medical Sciences is an academic health center focusing on medical education, research, and clinical programs. It offers various medical services, including specialized care in areas such as women's health, cancer treatment, orthopedics, stroke care, and trauma.

University of Arkansas for Medical Sciences is an academic health center focusing on medical education, research, and clinical programs. It offers various medical services, including specialized care in areas such as women's health, cancer treatment, orthopedics, stroke care, and trauma.

The Stark Neurosciences Research Institute is dedicated to improving outcomes for persons suffering from disorders of the nervous system.

Hillhurst Biopharmaceuticals specializes in developing innovative, liquid therapeutic gases for treating sickle cell disease. Their core technology enables the oral delivery of low-dose carbon monoxide, targeting the protective heme oxygenase system to reduce inflammation, prevent cell death, and halt hemoglobin polymerization. This approach addresses challenges associated with traditional inhaled gas therapies, such as caregiver exposure and imprecise dosing, ensuring accurate and safe administration.

Center for HIV Identification, Prevention, and Treatment Services is a research organisation that conducts HIV research. They offers customer support through email and phone contact.

L2P Research Labs is a preclinical contract research organization (CRO) that specializes in providing comprehensive research and development support. The company offers a range of preclinical and toxicology services, utilizing advanced technologies such as quantitative whole-body animal imaging, small animal ultrasound, MRI, and CT scans. L2P Research Labs also provides proprietary orthotopic and metastatic tumor models, enabling researchers to access a complete suite of research services tailored to their needs. Through its innovative approaches and state-of-the-art facilities, the company supports the advancement of scientific research in the fields of medicine and drug development.

Rational Vaccines is a preclinical stage company focused on developing innovative vaccines to address herpes simplex virus-related diseases. The company is dedicated to creating live-attenuated viral immunotherapeutics and prophylactic vaccine candidates aimed at reducing the spread of the virus and improving the management of symptoms associated with herpes infections. Through its research, Rational Vaccines aspires to revolutionize the treatment, prevention, and diagnosis of herpes and related conditions, ultimately enhancing the quality of life for individuals affected by these diseases.

AegirBio AB is a Swedish diagnostics company focused on developing innovative home testing solutions for oral health, therapeutic drug monitoring, and infectious diseases. The company has established a platform that enhances lateral flow tests, significantly improving their sensitivity and precision compared to traditional methods. AegirBio's product lineup includes the Veritope technology, which measures intact natalizumab for multiple sclerosis, alongside the MagniaReader, designed for both research and veterinary use. Their advancements enable robust, affordable, and easy-to-use testing instruments applicable across human health, veterinary, food safety, and environmental sectors. By leveraging novel techniques, AegirBio aims to expand the market for lateral flow tests and enhance patient care through more reliable diagnostics.

Clene Nanomedicine, established in 2012 and headquartered in Salt Lake City, Utah, is a clinical-stage biopharmaceutical company dedicated to developing innovative therapeutics for neurodegenerative diseases. The company has pioneered a unique nanotechnology drug platform that enables the creation of orally-administered neurotherapeutic drugs. This technology, known as Clean-Surface Nanosuspension, produces clean-surface nanocrystal medicines and serves as a foundation for a pipeline of new drug candidates aimed at addressing various diseases with significant unmet medical needs. Clene Nanomedicine's primary focus areas include demyelinating disorders and oncology.

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in New York, focused on developing innovative therapies for life-threatening diseases, particularly in the field of oncology. The company specializes in radiotherapies utilizing its alpha particle immunotherapy platform, which delivers radioisotopes through monoclonal antibodies to target and destroy cancer cells effectively. Its lead product candidate, Iomab-B, is undergoing a pivotal Phase III clinical trial as an induction and conditioning agent for patients over 55 with relapsed or refractory acute myeloid leukemia prior to hematopoietic stem cell transplantation. Additionally, Actinium is developing Actimab-A, which is in Phase II trials for newly diagnosed AML patients aged 60 and older, as well as Actimab-M for penta-refractory multiple myeloma currently in Phase I trials. The company also collaborates with Astellas Pharma to advance its research initiatives. Founded in 2000, Actinium Pharmaceuticals aims to address unmet medical needs in cancer treatment through its proprietary technologies.

Neurodon Corporation is a biopharmaceutical company focused on discovering and developing disease-modifying therapeutic candidates for intractable diseases. Established in 2019 and headquartered in Crown Point, Indiana, Neurodon specializes in molecular therapies that address endoplasmic reticulum (ER) stress, a significant factor in cell dysfunction and death. The company's innovative approach aims to restore calcium homeostasis through first-in-class modulators, addressing conditions such as Alzheimer's disease, Parkinson's disease, Huntington's disease, diabetes, and other rare diseases. Neurodon has made significant progress, with two candidates currently in IND-enabling studies and plans to enter clinical trials in 2025. The company has raised over $11 million through various funding sources, including state and federal grants, partnerships, and angel investments, and is actively seeking additional funding to support its first human studies for diabetes and rare disease programs.

SpineX Inc. is a clinical-stage medical device company focused on developing non-invasive neuromodulation technologies for individuals with neurological conditions. The company aims to address unmet medical needs by creating devices that support recovery and restoration of functions such as bladder, bowel, respiration, sexual, and sensorimotor capabilities. Their flagship device, the SCiP, is designed to treat neurological dysfunctions, particularly related to conditions like cerebral palsy. SpineX's commitment to advancing neuromodulation therapy stems from its goal to enhance the quality of life for patients recovering from strokes, spinal cord injuries, multiple sclerosis, traumatic brain injuries, and other related ailments.

South Rampart Pharma is a clinical-stage biotechnology company dedicated to developing safer alternatives for pain management. It focuses on creating novel, non-opioid and non-hepatotoxic molecules that target the midbrain's periaqueductal grey region to alleviate acute pain. The company's lead candidate, SRP-001, has received FDA Fast Track designation and aims to reduce risks associated with current pain medications, such as abuse potential and liver toxicity.

Glyphic Biotechnologies is a biotechnology company focused on developing an advanced protein sequencing platform that aims to enhance the understanding of human biology and diseases. Recognizing that while DNA offers valuable biological insights, it is proteins that provide critical information about bodily functions, Glyphic Biotechnologies is creating a next-generation sequencing technology. This innovative platform is designed to increase binding affinity and improve consistency, ultimately facilitating the creation of personalized and precision cancer vaccines for diverse patient populations. By enabling scientists and researchers to perform single-molecule, massively parallel protein sequencing, the company aims to support the development of novel therapeutics and diagnostics, paving the way for significant advancements in biomedical research and healthcare.

Subtle Medical, Inc. is a healthcare technology company based in Menlo Park, California, specializing in AI-powered medical imaging solutions. Founded in 2017, the company develops innovative software products such as SubtleMR and SubtlePET, which are designed to enhance image quality in magnetic resonance imaging (MRI) and positron emission tomography (PET) scans. These products utilize proprietary deep learning algorithms to reduce image noise and improve sharpness, thereby increasing efficiency and safety in clinical workflows. Subtle Medical's technology is FDA cleared and CE marked, and it operates on a vendor-agnostic AI infrastructure that integrates seamlessly with existing imaging systems. The company's mission is to enhance the quality, value, and accessibility of medical imaging by lowering costs, reducing imaging time, and minimizing radiation and contrast doses for patients.

Glyphic Biotechnologies is a biotechnology company focused on developing an advanced protein sequencing platform that aims to enhance the understanding of human biology and diseases. Recognizing that while DNA offers valuable biological insights, it is proteins that provide critical information about bodily functions, Glyphic Biotechnologies is creating a next-generation sequencing technology. This innovative platform is designed to increase binding affinity and improve consistency, ultimately facilitating the creation of personalized and precision cancer vaccines for diverse patient populations. By enabling scientists and researchers to perform single-molecule, massively parallel protein sequencing, the company aims to support the development of novel therapeutics and diagnostics, paving the way for significant advancements in biomedical research and healthcare.

The Buck Institute is the nation’s first independent research facility focused solely on understanding the connection between aging and chronic disease. Their mission is to increase the healthy years of life. At the Buck Institute, world-class scientists work in a uniquely collaborative environment to understand how normal aging contributes to the development of conditions specifically associated with getting older such as Alzheimer’s and Parkinson’s diseases, cancer, stroke, osteoporosis, heart disease, diabetes, macular degeneration and glaucoma. Their interdisciplinary approach brings scientists from disparate fields together to develop diagnostic tests and treatments to prevent or delay these maladies. The stakes have never been higher. While it’s true that people are living longer, those “extra” years are often marked by disability and pain. In addition to personal hardship, there is also a cost to society. The financial burden of treating the chronic diseases of aging is expected to rise steadily as Baby Boomers get older. There is an urgency to Their mission.

University of Oklahoma Health Sciences Center, as a comprehensive academic health center, is to educate students, residents, and other trainees in professional and graduate programs to become Oklahoma’s future team of healthcare leaders, clinicians, researchers, and educators; to advance distinctive basic, translational, clinical, and population research; to innovate and commercialize discoveries; and to deliver exceptional patient care across the full breadth of adult, women’s, and children’s specialties.

Morehouse School of Medicine, located in Atlanta, Georgia, is a distinguished institution focused on medical education, particularly for minority students. As a historically Black college and university (HBCU), it offers a range of degree programs, including medical degrees with specializations in fields such as Family Medicine, Internal Medicine, and Pediatrics, among others. In addition to its MD program, Morehouse provides master's degrees in Public Health and Biomedical Sciences, along with conducting significant research in areas like cardiovascular studies and health disparities. The institution emphasizes a commitment to diversity and offers scholarships to support disadvantaged students. The endowment fund managed by Morehouse School of Medicine plays a crucial role in funding scholarships, professorships, fellowships, and research initiatives, thereby enhancing its educational and public service missions.

Inherent Biosciences is a molecular diagnostics company focused on transforming the traditional trial and error approach in medicine. The company leverages its innovative epigenetic medicine platform to address various health challenges by identifying gene dysregulation and its associated pathways. By translating biological insights into actionable information, Inherent Biosciences aims to enhance treatment strategies for conditions such as pain, infertility, embryo quality, autism, rheumatoid arthritis, psoriatic arthritis, fetal heart disease, and COVID-19. This approach not only guides healthcare professionals in managing complex diseases but also seeks to provide personalized insights that empower patients in their health journeys.

Glyphic Biotechnologies is a biotechnology company focused on developing an advanced protein sequencing platform that aims to enhance the understanding of human biology and diseases. Recognizing that while DNA offers valuable biological insights, it is proteins that provide critical information about bodily functions, Glyphic Biotechnologies is creating a next-generation sequencing technology. This innovative platform is designed to increase binding affinity and improve consistency, ultimately facilitating the creation of personalized and precision cancer vaccines for diverse patient populations. By enabling scientists and researchers to perform single-molecule, massively parallel protein sequencing, the company aims to support the development of novel therapeutics and diagnostics, paving the way for significant advancements in biomedical research and healthcare.

Applied BioMath, LLC, established in 2013 and headquartered in Concord, Massachusetts, specializes in systems biology and pharmacology services aimed at accelerating drug research and development for biotechnology and pharmaceutical companies. The company employs advanced mathematical modeling and simulation techniques to provide predictive guidance and insights throughout the drug discovery process. Its offerings include pathway model development, target and biomarker discovery, and feasibility assessments for various drug targets. Additionally, Applied BioMath conducts analyses of competitor compounds and projects drug properties and dosing for clinical phases. The firm utilizes proprietary algorithms and high-performance computational biology to optimize decision-making and mitigate risks associated with late-stage attrition in drug development. With additional offices in Cambridge and Oakland, Applied BioMath collaborates strategically with industry leaders such as Sanofi and Xilio Therapeutics to enhance its service offerings.

iMetabolic Biopharma Corporation is an early-stage precision medicine company dedicated to developing innovative therapeutics for obesity-related diseases. Utilizing its proprietary iPlatform technology, the company aims to accelerate drug discovery and deliver affordable treatments to patients with high unmet medical needs.

Opsin Biotherapeutics specializes in the development of gene therapies based on opsins, a class of light-sensitive proteins. The company's primary focus is to create a pipeline of treatments for pain management, aiming to provide effective alternatives to opioids.

University of Arkansas for Medical Sciences is an academic health center focusing on medical education, research, and clinical programs. It offers various medical services, including specialized care in areas such as women's health, cancer treatment, orthopedics, stroke care, and trauma.

Kintara Therapeutics, Inc. is a clinical-stage drug development company focused on creating and commercializing innovative anti-cancer therapies for patients with unmet medical needs. The company is advancing two late-stage therapeutics: VAL-083, a DNA-targeting agent designed to treat drug-resistant solid tumors such as glioblastoma multiforme and ovarian cancer, and REM-001, a photodynamic therapy aimed at cutaneous metastatic breast cancer. Kintara has established a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. for the manufacturing and sales of VAL-083 in China. Kintara Therapeutics was founded in 2009 and is headquartered in San Diego, California. The company seeks to address significant challenges faced by cancer patients who have not responded to conventional treatments.

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company based in Houston, Texas, that focuses on developing and commercializing T cell-based immunotherapies and peptide-based vaccines for hematological malignancies and solid tumors. The company’s MultiTAA technology enhances the effectiveness of non-engineered tumor-specific T cells, enabling them to target multiple tumor-associated antigens simultaneously. This approach aims to prevent immune escape and foster durable immunity. Marker Therapeutics offers autologous T cell therapies for conditions such as lymphoma and multiple myeloma, while also developing allogeneic T cell therapies for acute myeloid leukemia and acute lymphoblastic leukemia. Additionally, the company is advancing peptide-based vaccines, including TPIV100/110 and TPIV200, which are currently in Phase II clinical trials for treating breast and ovarian cancers, respectively.

The University of Texas MD Anderson Cancer Center is a leading institution dedicated exclusively to cancer patient care, research, education, and prevention. Located in the Texas Medical Center in Houston, Texas, it was established as one of the original three comprehensive cancer centers under the National Cancer Act of 1971. MD Anderson serves as both a degree-granting academic institution and a specialized cancer treatment facility. It is affiliated with two prominent medical schools: The University of Texas Medical School at Houston and Baylor College of Medicine. Renowned for its exceptional cancer care, MD Anderson has consistently ranked among the top cancer hospitals in the United States, earning the No. 1 position in U.S. News & World Report's "Best Hospitals" survey for ten of the past twelve years. The center is widely recognized for its commitment to advancing cancer treatment and improving patient outcomes.

The University of Alabama at Birmingham (UAB), established in 1969, is a distinguished institution located in Birmingham, Alabama. It offers a diverse range of over 130 undergraduate and graduate programs, including degrees in the arts, sciences, business, education, engineering, and public health. UAB is particularly renowned for its medical school, which encompasses one of the largest university medical centers in the United States. The university has produced numerous scholars and award recipients, such as Fulbright, Rhodes, and Truman scholars, reflecting the high caliber of its education. Student life at UAB is dynamic, featuring more than 150 student organizations, an active Greek community, and a top-ranking recreation and fitness center, alongside year-round intramural sports. Most students reside in on-campus housing, and UAB provides financial aid and departmental fellowships to support those in need of tuition assistance. Through its commitment to education, research, and community service, UAB addresses both local and global challenges while fostering a culture of discovery and innovation.

Shirley Ryan AbilityLab is a translational research hospital. Their services include spinal cord injury recovery, brain injury recovery, COVID recovery, pediatric and adolescent rehabilitation, nursing, cancer rehabilitation, limb loss and impairment, and pain management.

Domus Diagnostics is a healthcare company based in Park City, Utah, founded in 2021. It specializes in providing a care diagnostics platform focused on respiratory disease home testing services. The company's devices are designed for everyday infectious disease testing and support governments and institutions in conducting large-scale testing during new infectious disease outbreaks. This approach aims to facilitate early treatment and prevent the spread of diseases, potentially mitigating pandemic-scale impacts.

Aphios Corporation is a biotechnology company based in Woburn, Massachusetts, specializing in drug delivery platforms and the development of quality-of-life medicines. The company focuses on enhancing drug discovery and manufacturing through its innovative biotechnology and nanotechnology solutions. Aphios offers a range of therapeutic products aimed at health maintenance, disease prevention, and the treatment of various conditions, including cancers, infectious diseases, and central nervous system disorders. Notable products include Zindol, a ginger-based product, and various formulations of Taxotere for cancer treatment, which aim to improve oral bioavailability and target specific cancer cells. In addition to its therapeutic offerings, Aphios develops advanced technologies such as SuperFluids for pharmaceutical manufacturing and virology testing services, contributing to the safety and efficacy of drug therapies. Founded in 1993, Aphios continues to push the boundaries of medical science with its focus on innovative solutions for complex health challenges.

Health 360x brings together patients, clinicians, and researchers to enhance the health of neglected groups. Health 360x is changing clinical research through point-of-care access for patients and providers in non-academic practices that mostly serve African Americans and other patients who have historically been underrepresented in corporate and NIH clinical trials.

Washington University School of Medicine is the medical school of Washington University in St. Louis.A leader in medical research, teaching and patient care, Washington University School of Medicine is currently ranked fourth in the nation by U.S. News & World Report. The School’s 2,100 employed and volunteer faculty physicians and clinicians -- known as Washington University Physicians -- are also medical staff members of Barnes-Jewish and St. Louis Children’s hospitals. The clinical practice group provides care to more than 430,000 children and adults at 49 clinical sites annually. Together, the institutions located on the Washington University Medical Center campus employ more than 21,000 clinicians, scientists, residents, fellows, administrators and support staff.

The University of Alabama at Birmingham (UAB), established in 1969, is a distinguished institution located in Birmingham, Alabama. It offers a diverse range of over 130 undergraduate and graduate programs, including degrees in the arts, sciences, business, education, engineering, and public health. UAB is particularly renowned for its medical school, which encompasses one of the largest university medical centers in the United States. The university has produced numerous scholars and award recipients, such as Fulbright, Rhodes, and Truman scholars, reflecting the high caliber of its education. Student life at UAB is dynamic, featuring more than 150 student organizations, an active Greek community, and a top-ranking recreation and fitness center, alongside year-round intramural sports. Most students reside in on-campus housing, and UAB provides financial aid and departmental fellowships to support those in need of tuition assistance. Through its commitment to education, research, and community service, UAB addresses both local and global challenges while fostering a culture of discovery and innovation.

Scene Health is a healthcare company dedicated to addressing the longstanding issue of medication nonadherence through an innovative approach that combines technology, science, and personalized support. Formerly known as Emocha Health, the company enhances the standard of care known as Directly Observed Therapy by offering a comprehensive model of care that includes personalized video coaching, education, and motivational content. Its mobile app facilitates daily video check-ins, allowing patients to connect with a dedicated care team of pharmacists, nurses, and health coaches from anywhere at any time. Scene Health engages over 120 customers across the healthcare sector, focusing on improving medication adherence for individuals with chronic and infectious diseases. By empowering patients to identify and overcome barriers to adherence, particularly those related to social determinants of health, Scene Health aims to significantly improve health outcomes while addressing the $500 billion challenge of medication nonadherence.

Feinstein Institute For Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State. Home to 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine.

TransCode Therapeutics, founded in 2016 and based in Boston, Massachusetts, is a biopharmaceutical company dedicated to discovering, developing, and commercializing microRNA (miRNAs) therapeutics for treating metastatic cancer. The company's core focus lies in its proprietary TTX nanoparticle platform, which enables the intelligent design and effective delivery of RNA therapeutics targeting specific miRNAs. TransCode's lead candidate, TTX-MC138, targets microRNA-10b, a validated biomarker of metastasis across multiple tumor types. By inhibiting this miRNA, TransCode aims to eradicate metastatic tumor cells and combat cancer progression.

OncoSpherix, Inc., based in Atlanta, Ga, is a pre-clinical stage oncology drug development company that is advancing a proprietary platform of first-in-class small molecule therapeutics that are designed to improve the quality of life and survival for people with many forms of cancer by targeting a common feature of solid tumors: the activation of hypoxia inducible factor-1 (HIF-1). Nearly all solid cancers grow faster than their blood supply, leading to regions of low oxygen in the tumors and HIF activation. The HIFs in turn induce the expression of over 100 genes that help tumor cells survive and spread. OncoSpherix has several classes of small molecules that block activation of HIF-1 through novel mechanisms. OncoSpherix’s lead clinical candiate has been shown in mouse models to reduce primary tumor growth, inhibit metastases, and prolong survival in many types of cancer (glioblastoma, pancreatic cancer, uveal melanoma, lung cancer, breast cancer). Importantly, the agents are well tolerated and can be combined with therapeutics that work in well oxygenated regions of cancers, leading to dramatically enhanced cancer control.

Arkansas Children's Research Institute is a not-for-profit organization affiliated with Arkansas Children's, Inc., and is dedicated to advancing pediatric health through research. It operates in conjunction with Arkansas Children's Hospital, the only pediatric medical center in Arkansas and one of the largest in the nation, which spans 29 city blocks and features 370 beds. The hospital employs around 500 physicians and more than 4,400 staff members, focusing on innovative medical research, surgical procedures, and intensive treatments aimed at improving children's health and development. The institute's research efforts contribute to the hospital's reputation for medical breakthroughs and have garnered recognition, including being ranked on the FORTUNE 100 Best Companies to Work For list for three consecutive years.

The Oklahoma Medical Research Foundation (OMRF) is a non-profit biomedical research institute dedicated to understanding and treating various devastating illnesses, including Alzheimer's, heart disease, lupus, multiple sclerosis, and cancer. It operates a research facility, providing services and access to resources that facilitate drug discoveries and improve patient care.

Chemeleon is a company that has developed an innovative platform technology for rapid and affordable diagnostics capable of detecting a wide array of analytes, including drugs, proteins, and viruses. Their proprietary in vitro diagnostic format delivers a colorimetric readout within minutes, visible to the naked eye, and does not require reagents, instruments, or specialized training. This decentralized testing approach empowers clinicians to extend point-of-care diagnostics and allows individuals to self-administer tests at the point of need. Chemeleon's diagnostics utilize highly selective molecular receptors combined with colorimetric nanomaterial reporters, facilitating immediate and actionable diagnoses that can significantly improve patient outcomes while reducing healthcare costs. Notably, the company developed a diagnostic for detecting beta-2-transferrin, a biomarker for Cerebrospinal Fluid leaks, resulting in substantial reductions in morbidity and healthcare expenses. With a focus on providing specificity and selectivity comparable to lab-based tests but in a fraction of the time and cost, Chemeleon's technology stands to transform healthcare accessibility, especially in resource-limited environments.

Linshom is a healthcare technology company that develops wearable, FDA-cleared sensors for continuous, predictive respiratory monitoring at the patient's bedside or home. Their core product, an operating room quality respiratory profile, enables early detection of respiratory decline, reducing costly rapid response activations and ICU transfers, thereby improving patient outcomes and lowering healthcare costs.

Aptinyx Inc. is a clinical-stage biopharmaceutical company based in Evanston, Illinois, that specializes in discovering and developing innovative therapies for disorders of the brain and nervous system. Founded in 2015, the company focuses on proprietary synthetic small molecules that modulate the NMDA receptor, enhancing nerve cell communication. Aptinyx's pipeline includes NYX-2925, which is in Phase II clinical development for painful diabetic peripheral neuropathy and fibromyalgia, and NYX-783, currently in Phase I trials for post-traumatic stress disorder. Additionally, NYX-458, another NMDA receptor modulator, is undergoing Phase I studies aimed at treating cognitive impairment associated with Parkinson's disease. The company also collaborates with Allergan plc to develop a compound for major depressive disorder, highlighting its commitment to addressing significant unmet medical needs in the central nervous system arena.

Feinstein Institute For Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State. Home to 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine.

University of Arkansas for Medical Sciences is an academic health center focusing on medical education, research, and clinical programs. It offers various medical services, including specialized care in areas such as women's health, cancer treatment, orthopedics, stroke care, and trauma.

Neurovations, a patient care and innovation company, was founded in 1992 by CEO Dr. Eric Grigsby. Today, Neurovations is a national leader in medical device and pharmaceutical innovation, clinical research, and a world-class education program focusing in pain and neuroscience. Dr. Grigsby is deeply connected to the healthcare community through our non-profit HealthRoots Foundation. Our unwavering mission is to inspire hope and to contribute to the health and well-being of our patients and communities through integrated clinical practice, research, and education.

The Georgia Clinical & Translational Science Alliance (Georgia CTSA) is an inter-institutional magnet that concentrates basic, translational, and clinical research investigators, community clinicians, professional societies, and industry collaborators in dynamic clinical and translational research projects. Emory engaged three of its close academic partners - Morehouse School of Medicine (MSM), Georgia Institute of Technology (Georgia Tech), and the University of Georgia (UGA) - to form the Georgia CTSA. This partnership, a strategic multi-institutional alliance, offers compelling, unique, and synergistic advantages to research and patients statewide. Emory is a national leader in healthcare and biomedical research as well as an outstanding leader in clinical and translational research training and education. Morehouse School of Medicine is a nationally recognized historically black institution that brings ethnic diversity to biomedical research, addresses health disparities through successful community engagement research, and serves as a pipeline for training minority researchers. Georgia Tech is a national leader in biomedical engineering and the application of innovative systems engineering to healthcare solutions. UGA has a proven track record in outstanding basic and translational research and, as the State’s land-grant institution, offers a robust statewide network that enhances community outreach, service, and research. These institutions extend their current partnerships in healthcare, education, and cutting-edge interdisciplinary research to synergize Georgia CTSA. Created in 2017 as one of a national consortium striving to improve the way biomedical research is conducted across the country. The consortium, funded through the National Center for Advancing Translational Sciences, part of the National Institutes of Health's Clinical and Translational Science Awards (CTSA), shares a common vision to translate laboratory discoveries into treatments for patients, engage communities in clinical research efforts and train the next generation of clinical investigators.

The Indiana University School of Medicine is the largest medical school in the United States. The IU School of Medicine, which is made up of five fundamental science departments and twenty clinical departments, provides superior training for students interested in pursuing a medical degree. The school launched a new medical education curriculum with the Class of 2020 that better represents the modern U.S. health care environment and delivery methods, preparing students to practice medicine in a team-based, multidisciplinary setting.

Allen Institute for Brain Science is a non-profit medical research organization dedicated to understanding the complexities of bioscience. The organization encompasses three entities, the Allen Institute for Brain Science, Allen Institute for Cell Science, and Paul G. Allen Frontiers Group. Its mission is to accelerate the understanding of how the brain works in health and disease. It creates useful public resources, drive technological and analytical advances, and discover fundamental brain properties through integration of experiments using a big science, team science, and open science approach. Allen Institute for Brain Science was founded on 2003 and is based in Seattle, Washington.

Wake Forest School of Medicine is an educational institution based in Winston Salem, North Carolina, founded in 1902. It specializes in biomedical research and offers primary care education and training, with students gaining hands-on experience with patients from their first week of medical school. The school also provides tertiary care, which is crucial for a research and teaching hospital. Wake Forest School of Medicine has a nationally recognized research program, attracting over $400 million in extramural funding annually. It educates nearly 1,900 students and fellows, including physicians, basic scientists, and allied clinical professionals.

Arkana Laboratories offers renal pathology, neuropathology and testing, apol1, and biopharmaceutical services. It is a provider of esoteric pathologic services and a centre for pathology focused on improving care for patients. For inquiries, email, telephone numbers, and physical addresses are available on their website.

Evaxion Biotech A/S is a clinical-stage biotechnology company focused on leveraging artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer and infectious diseases. Utilizing its proprietary AI-immunology technology, the company is advancing a diverse pipeline of product candidates, which includes three patient-specific cancer immunotherapies, two of which are currently in Phase I/IIa clinical development. In addition to its cancer therapies, Evaxion is also working on a portfolio of vaccines aimed at preventing bacterial and viral infections, with one program in preclinical development targeting Methicillin-resistant Staphylococcus aureus and related skin and soft tissue infections. The company's innovative approach aims to enhance treatment efficacy for patients with unmet medical needs.

Glyphic Biotechnologies is a biotechnology company focused on developing an advanced protein sequencing platform that aims to enhance the understanding of human biology and diseases. Recognizing that while DNA offers valuable biological insights, it is proteins that provide critical information about bodily functions, Glyphic Biotechnologies is creating a next-generation sequencing technology. This innovative platform is designed to increase binding affinity and improve consistency, ultimately facilitating the creation of personalized and precision cancer vaccines for diverse patient populations. By enabling scientists and researchers to perform single-molecule, massively parallel protein sequencing, the company aims to support the development of novel therapeutics and diagnostics, paving the way for significant advancements in biomedical research and healthcare.

Oligomerix, Inc. is a biopharmaceutical company based in Bronx, New York, founded in 2006. The company focuses on developing therapeutics for Alzheimer's disease and related neurodegenerative disorders, particularly targeting tau proteins. Oligomerix specializes in small molecule drug discovery, with programs centered on tau oligomers and tau protease inhibitors. Additionally, the company creates antibody fragments that serve as biomarkers for drug development, diagnostic, and therapeutic applications. By leveraging its innovative research, Oligomerix aims to identify and validate new drug targets, facilitating the development of disease-modifying treatments for various tauopathies, including progressive supranuclear palsy and frontotemporal dementia.

Arkansas Children's Research Institute is a not-for-profit organization affiliated with Arkansas Children's, Inc., and is dedicated to advancing pediatric health through research. It operates in conjunction with Arkansas Children's Hospital, the only pediatric medical center in Arkansas and one of the largest in the nation, which spans 29 city blocks and features 370 beds. The hospital employs around 500 physicians and more than 4,400 staff members, focusing on innovative medical research, surgical procedures, and intensive treatments aimed at improving children's health and development. The institute's research efforts contribute to the hospital's reputation for medical breakthroughs and have garnered recognition, including being ranked on the FORTUNE 100 Best Companies to Work For list for three consecutive years.

Feinstein Institute For Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State. Home to 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine.

The Oklahoma Medical Research Foundation (OMRF) is a non-profit biomedical research institute dedicated to understanding and treating various devastating illnesses, including Alzheimer's, heart disease, lupus, multiple sclerosis, and cancer. It operates a research facility, providing services and access to resources that facilitate drug discoveries and improve patient care.

Eliaz Therapeutics is focused on developing innovative medical devices aimed at treating life-threatening diseases that are currently difficult to manage. The company's flagship device utilizes a patented apheresis column designed to selectively remove galectin-3 from human blood. This device targets both bound and free galectin-3, a protein linked to various serious health conditions, including diabetes, chronic kidney disease, organ fibrosis, and cancer. By efficiently eliminating galectin-3 from the bloodstream, the device offers a less invasive treatment option with fewer side effects compared to traditional therapies. Its design leverages a proprietary capturing molecule and is compatible with existing hospital systems, facilitating its adoption in clinical settings.

Reliant Glycosciences is a biotechnology company dedicated to developing diagnostic and prognostic tools specifically for patients with IgA nephropathy. The company focuses on creating assays that identify biomarkers associated with this condition, which possess diagnostic and prognostic value. By characterizing disease-specific biomarkers, Reliant Glycosciences aims to facilitate the development and testing of innovative, targeted therapies for IgA nephropathy. This approach not only supports the advancement of transformative treatments but also enhances the overall understanding of the disease, ultimately benefiting patients affected by this condition.

Immunicom, Inc. is a clinical research company based in San Diego, California, founded in 2013. It focuses on innovative, non-pharmaceutical treatment approaches aimed at cancer, inflammatory diseases, and autoimmune diseases. The company has developed a therapeutic blood-filtering device designed to effectively treat various cancer types, including those resistant to conventional treatments. This device not only helps in directly targeting cancer cells but also enhances the efficacy of concurrent cancer therapies, potentially resulting in fewer side effects compared to traditional drug and biological-based immunotherapies.

AVM Biotechnology LLC is a clinical-stage regenerative medicine company based in Seattle, Washington, focused on the discovery, development, and commercialization of innovative stem cell technologies. Founded in 2008 and led by Dr. Theresa Deisher, the company specializes in creating novel compounds aimed at enhancing organ regeneration and immune system recovery. Its offerings include a range of platforms such as Boutique Biologics, which provides personalized medicine through patient-specific biologics, and Better Biologics, designed for large-scale manufacturing of human biologics to address resistance issues associated with non-human cells. The company's lead drug, an advanced formulation of dexamethasone, aims to mobilize the body's immune cells to target cancer, autoimmune disorders, and infectious diseases. AVM Biotechnology's commitment to addressing complex medical challenges is bolstered by a Scientific Advisory Board comprised of experts in cancer and immunology.

NovoMedix is a biotechnology company focused on developing novel orally available small molecules to address fibrotic disorders and certain cancer types. The company utilizes a proprietary technology platform that includes a library of small-molecule inhibitors, which have demonstrated significant efficacy in animal models for both fibrosis and cancer. Notably, some of these compounds co-target pathways that offer cardioprotective benefits and enhance the effectiveness of standard chemotherapies for triple negative breast cancer. This dual action aims to improve patient responses to treatment while significantly reducing the cardiotoxic effects commonly associated with chemotherapies, such as doxorubicin. As cardiovascular disease is a leading cause of death among breast cancer survivors, NovoMedix's approach prioritizes long-term patient health by addressing both cancer and associated heart risks. The company is working towards initiating IND enabling studies for its lead candidate, with the objective of delivering a safe and effective therapy to patients as soon as possible.

Modality.AI, Inc. is a healthcare technology company based in San Francisco, California, founded in 2018. It specializes in AI-powered solutions that enhance the efficiency of clinical trials for neurological and mental health therapies. The company's platform utilizes conversational AI to engage patients through naturalistic spoken interaction, allowing for continuous health assessments anytime and anywhere. By analyzing multimodal data, including audio-visual biomarkers, Modality.AI provides objective measures that correlate with clinical outcomes. This innovative approach enables pharmaceutical companies to conduct self-driven assessments and improve the monitoring of health conditions, ultimately facilitating more effective clinical trials.

University of Arkansas for Medical Sciences is an academic health center focusing on medical education, research, and clinical programs. It offers various medical services, including specialized care in areas such as women's health, cancer treatment, orthopedics, stroke care, and trauma.

Benaroya Research Institute at Virginia Mason (BRI) is one of the few research institutes in the world dedicated to discovering causes and cures to eliminate autoimmune and immune system diseases. At BRI, their scientists aren’t focused on eliminating one or two autoimmune diseases—they’re taking on all 80. Because autoimmune diseases are connected, so is the way they’re fighting them. They're applying the breakthroughs they make against individual autoimmune diseases to make progress against them all. Through collaboration and cooperation between researchers, across clinical trials and with other institutions, they connect laboratory research to clinical trials and translate discoveries to real-life applications. As a world leader in scientific innovation, they’re leveraging this progress to eliminate autoimmune and immune system diseases in the future. Their discoveries are also having significant impact on people living with autoimmune and immune system diseases today—by improving the ability to predict disease risk, facilitate treatment, decrease progression of these diseases and make related therapies safer and more effective.

Dascena, Inc. is a healthcare technology company based in Oakland, California, that specializes in developing machine learning algorithms aimed at enhancing disease detection and improving patient care outcomes. Established in 2018, Dascena's flagship product, AlgoDiagnostics, autonomously processes electronic health record data to facilitate early intervention for conditions such as acute decompensation, sepsis, and acute kidney injury. The company focuses on addressing unmet healthcare needs through its innovative solutions in clinical decision support, point-of-care diagnostics, and biopharma companion diagnostics. By leveraging intensive clinical research, Dascena aims to enable clinical practitioners to make timely and accurate interventions, ultimately saving lives and enhancing the delivery of care.

Weill Cornell Medicine operates as a prestigious medical and graduate school in New York City, dedicated to excellence in education, patient care, and scientific discovery. The institution provides a wide array of services, including medical consultancy, healthcare programs, and educational opportunities for future physicians and medical professionals. It is also involved in the management of specialized treatment centers, such as the Weill Cornell Vein Treatment Center, which addresses various venous conditions and related health issues. In addition to its clinical services, Weill Cornell Medicine emphasizes the integration of advanced technology in its operations, supported by a robust Information Technologies & Services Department. This department enhances the institution's mission by providing comprehensive IT infrastructure and support, including the development of innovative applications for clinical and research projects. Through its multidisciplinary approach, Weill Cornell Medicine serves as a vital resource for healthcare providers, medical students, and researchers, facilitating access to medical education and advisory services across various health-related fields.

Genomenon, Inc. is a software development company based in Ann Arbor, Michigan, that specializes in tools for genetic diagnosis and discovery. Founded in 2014, it provides a suite of diagnostic and discovery solutions that enable physicians, researchers, and pharmaceutical companies to rapidly and accurately identify disease-causing variants from genomic sequencing data. The company’s flagship product, GENOMENON, automates the analysis of next-generation sequencing data, thereby enhancing decision-making processes in clinical settings and accelerating discoveries in genomics. With its focus on improving cancer diagnosis and treatment, Genomenon aims to support better patient outcomes through its innovative software solutions.

Meridian Bioscience is an integrated life science company that develops, manufactures, and distributes clinical diagnostic test kits for gastrointestinal, viral, respiratory, and parasitic infectious diseases. The company specializes in molecular and immunological reagents, providing tools that support the discovery and diagnosis of various medical conditions. In addition to diagnostic test kits, Meridian offers bulk antigens, antibodies, PCR and qPCR reagents, nucleotides, and bioresearch reagents, serving researchers and other diagnostic manufacturers. Moreover, the company engages in contract development and manufacturing of proteins and other biologicals under cGMP conditions, catering to biopharmaceutical and biotechnology firms involved in drug and vaccine research. Meridian operates through three segments: U.S. Diagnostics, European Diagnostics, and Life Science, emphasizing its commitment to enhancing healthcare outcomes through innovative solutions.